2026 MaTOS GU | Session II | Renal Cell Carcinoma
Overview
Dr. Braun reviewed kidney cancer biomarkers: histology, DNA, gene expression, KIM-1, and imaging guide therapy; integrated approaches improve outcomes.
Dr. Ornstein highlighted HIF2α+TKI combos in RCC: strong response rates and tolerability; OS data needed to define impact on treatment strategy.
Dr. Berg outlined the adaptive PDIGREE trial: >1,000 ccRCC pts; nivo±ipi first-line; aims to improve outcomes beyond CR/PD; OS primary endpoint.
Dr. Vaena reviewed tivozanib in refractory RCC: improves PFS (~5.6 mo), limited OS benefit; effective in later lines, with ongoing adjuvant studies.
The panel discussed RCC combos: balancing efficacy/toxicity, need for durable first-line responses, biomarker limits, dosing concerns, and adaptive trials.
Dr. Ornstein highlighted HIF2α+TKI combos in RCC: strong response rates and tolerability; OS data needed to define impact on treatment strategy.
Dr. Berg outlined the adaptive PDIGREE trial: >1,000 ccRCC pts; nivo±ipi first-line; aims to improve outcomes beyond CR/PD; OS primary endpoint.
Dr. Vaena reviewed tivozanib in refractory RCC: improves PFS (~5.6 mo), limited OS benefit; effective in later lines, with ongoing adjuvant studies.
The panel discussed RCC combos: balancing efficacy/toxicity, need for durable first-line responses, biomarker limits, dosing concerns, and adaptive trials.
Target Audience
Physicians
This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.
Faculty
Speakers and Panelists:
David A. Braun, MD, PhD
Moshe Ornstein, MD, MA
Stephanie A. Berg, DO
Daniel Vaena, MD
Date of Release
March 20th, 2026
%2016.47.03-1770752981975.webp&w=3840&q=75)
